Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis

By LabMedica International staff writers
Posted on 15 Oct 2026

Sepsis and severe infections are difficult to treat because patients with similar clinical presentations may have very different underlying immune responses. More...

Corticosteroids are commonly used in severe infection, septic shock, viral pneumonia, and pandemic settings, but treatment benefit can vary considerably between patients. To better guide therapy, a newly evaluated host-response approach aims to identify patients with severe infection or suspected sepsis who may be more likely to benefit from corticosteroids.

Inflammatix, Inc. (Sunnyvale, CA, USA) has received a $1 million development contract from the Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response. The contract will support Project Compass, which will evaluate the TriVerity host-response test as a platform for predicting corticosteroid responsiveness in patients with severe infections and suspected sepsis. TriVerity is cleared by the U.S. Food and Drug Administration (FDA) for its current diagnostic and triage use, but use of TriVerity to predict response to corticosteroid therapy is investigational and has not been cleared or approved by the FDA.

The TriVerity Test System includes a disposable TriVerity cartridge and the Myrna instrument. The test measures 29 host messenger RNAs from whole blood and uses machine learning-derived algorithms to interpret the body’s immune response to infection. In approximately 30 minutes, it generates three scores indicating the likelihood of bacterial infection, likelihood of viral infection, and illness severity in adult emergency department patients with suspected acute infection or sepsis.

Project Compass builds on earlier retrospective analyses of independent sepsis clinical trial datasets that suggested corticosteroid response may differ according to TriVerity illness severity classification. Patients in the highest Illness Severity band appeared more likely to experience clinical benefit from corticosteroid therapy, while those in lower severity bands may derive less benefit and could potentially be harmed. The new project will further evaluate this hypothesis in well-characterized patient cohorts, both on-device using the FDA-cleared Myrna platform and in silico using locked TriVerity algorithms.

“Inflammatix was founded on a simple belief: the body often knows more about disease than we can currently see. With Project Compass, we are asking an important next question: can we use that immune signal not only to understand infection and severity earlier, but also to help determine which therapy is right for which patient? If successful, this work could move sepsis care beyond broad, one-size-fits-all treatment and toward real-time, host-response-guided precision medicine,” said Tim Sweeney, MD, PhD, co-founder and CEO of Inflammatix.

Related Links
Inflammatix


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.